Plain-English translation of NCT05753839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether surgery to remove the affected kidney—done either before or after starting immunotherapy with nivolumab plus ipilimumab—can help people with advanced kidney cancer live longer and stay healthier. Researchers want to know if combining surgery with this newer immunotherapy medication works better than using the medication alone.
For years, doctors weren't sure whether surgery to remove the kidney helped patients with advanced kidney cancer, especially now that newer immunotherapy medications are available. This trial will help answer whether adding surgery to this treatment plan makes a real difference.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups: surgery before starting the immunotherapy medication, immunotherapy medication first followed by surgery later, or immunotherapy medication alone. The study involves regular visits to receive treatment and have blood tests and scans to monitor your response. Your participation will continue as long as the treatment is helping and you're tolerating it well.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
South Korea